Search
Intellia Therapeutics Inc
NTLAAdd to Watchlist
11.660USD
-0.810-6.50%
Close 11-02 16:00（ET）
1.63BMarket Cap
LossP/E TTM
Intellia Therapeutics Inc (NTLA) Stock Price Target & Forecast
Analyst Rating
Based on 19 analysts giving stock ratings to Intellia Therapeutics Inc in the past month.
Hold
2 Strong Buy
7 Buy
6 Hold
3 Sell
1 Strong Sell
Target Price
23.813USD+78.77%
NTLA Analyst Recommendation Trends
In the current month, NTLA has received 7 Buy Ratings, 6 Hold Ratings, and 3 Sell Ratings. NTLA average Analyst price target in the last month is 23.813.
2026-11
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2
2
2
2
3
3
4
4
7
7
7
6
7
7
8
8
6
6
6
7
9
10
10
10
1
1
1
1
0
0
0
0
3
3
2
2
2
2
2
2
19
19
18
18
21
22
24
24
NTLA Analyst Rating for Peer Comparison
Updated: Nov 1, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
0
0
27
argenx SE
ARGX
10
14
3
0
0
27
Ionis Pharmaceuticals Inc
IONS
6
14
5
0
0
25
Insmed Inc
INSM
7
18
0
0
0
25
Revolution Medicines Inc
RVMD
10
14
1
0
0
25
Kymera Therapeutics Inc
KYMR
9
13
2
0
0
24
CRISPR Therapeutics AG
CRSP
4
8
11
0
0
23
Tempus AI Inc
TEM
4
7
11
0
1
23
Biontech SE
BNTX
4
11
8
0
0
23
IQVIA Holdings Inc
IQV
8
12
3
0
0
23
Financial Forecasting
Based on analysts' estimates, NTLA EPS is projected to reach -0.797 in FY2026Q3, following reported EPS of -0.799 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.95
-0.91
-0.80
-0.80
-0.77
Actual
-0.83
-0.81
-0.80
--
--
Surprise
+13.51%
+11.12%
+0.05%
--
--
FAQs
What is Intellia Therapeutics Inc's expected revenue for the next quarter?
Intellia Therapeutics Inc's expected revenue is 10.46M.
What is Intellia Therapeutics Inc's price target?
Analysts forecast that Intellia Therapeutics Inc's price target is USD 23.81, with the highest forecast at USD 61.00 and the lowest forecast at USD 8.00.
How have Intellia Therapeutics IncNTLA's recent earnings per share performed?
The market expectation was USD -0.80, while Intellia Therapeutics IncNTLA's earnings per share (EPS) for the previous quarter was USD -0.81. EPS for the next quarter is expected at USD -0.80.
What is the analyst rating for Intellia Therapeutics Inc?
Based on the ratings of Intellia Therapeutics Inc's stock from 19 analysts, most analysts support a signal_hold trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as signal_hold. Please note that this is not trading advice. You still need to conduct your own analysis.